174 related articles for article (PubMed ID: 34740486)
1. Immunohistochemistry as predictive and prognostic markers for gastrointestinal malignancies.
Rosenbaum MW; Gonzalez RS
Semin Diagn Pathol; 2022 Jan; 39(1):48-57. PubMed ID: 34740486
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 evaluation in the gastrointestinal tract: from biological rationale to its clinical application.
Mastracci L; Grillo F; Parente P; Gullo I; Campora M; Angerilli V; Rossi C; Sacramento ML; Pennelli G; Vanoli A; Fassan M
Pathologica; 2022 Oct; 114(5):352-364. PubMed ID: 36305021
[TBL] [Abstract][Full Text] [Related]
3. Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status.
Wang L; Zhang Q; Ni S; Tan C; Cai X; Huang D; Sheng W
Cancer Med; 2018 Jun; 7(6):2612-2620. PubMed ID: 29673110
[TBL] [Abstract][Full Text] [Related]
4. Off-label use of common predictive biomarkers in gastrointestinal malignancies: a critical appraisal.
Tessier-Cloutier B; Cai E; Schaeffer DF
Diagn Pathol; 2019 Jun; 14(1):62. PubMed ID: 31221175
[TBL] [Abstract][Full Text] [Related]
5. Loss of switch/sucrose non-fermenting complex protein expression in undifferentiated gastrointestinal and pancreatic carcinomas.
Tessier-Cloutier B; Schaeffer DF; Bacani J; Marginean CE; Kalloger S; Köbel M; Lee CH
Histopathology; 2020 Jul; 77(1):46-54. PubMed ID: 32413172
[TBL] [Abstract][Full Text] [Related]
6. Applicability and interpretation of HER2/Neu & PD-L1 stains in gastrointestinal tract tumours.
Das P; Mehra L
Indian J Pathol Microbiol; 2021 Jun; 64(Supplement):S2-S3. PubMed ID: 34135132
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK/EML4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinoma.
Schmoeckel E; Hofmann S; Fromberger D; Rottmann M; Luthardt B; Burges A; Jeschke U; Kirchner T; Lax SF; Mayr D
Virchows Arch; 2019 May; 474(5):599-608. PubMed ID: 30734108
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Utility of Tumor-Infiltrating Lymphocytes in Noncolorectal Gastrointestinal Malignancies.
Hamza A; Khan U; Khurram MS; Abraham R; Mazzara P; Hadid T; Kafri Z
Int J Surg Pathol; 2019 May; 27(3):263-267. PubMed ID: 30426804
[TBL] [Abstract][Full Text] [Related]
10. Expression of neural cell adhesion molecule L1 (CD171) in neuroectodermal and other tumors: An immunohistochemical study of 5155 tumors and critical evaluation of CD171 prognostic value in gastrointestinal stromal tumors.
Inaguma S; Wang Z; Lasota JP; Miettinen MM
Oncotarget; 2016 Aug; 7(34):55276-55289. PubMed ID: 27419370
[TBL] [Abstract][Full Text] [Related]
11. MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications.
Hacking S; Jin C; Komforti M; Liang S; Nasim M
Pathol Res Pract; 2019 Oct; 215(10):152552. PubMed ID: 31353229
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers for personalized medicine in GI cancers.
Zhang SY; Zhang SQ; Nagaraju GP; El-Rayes BF
Mol Aspects Med; 2015 Nov; 45():14-27. PubMed ID: 26054566
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry.
El Jabbour T; Ross JS; Sheehan CE; Affolter KE; Geiersbach KB; Boguniewicz A; Ainechi S; Bronner MP; Jones DM; Lee H
J Clin Pathol; 2018 Jan; 71(1):46-51. PubMed ID: 28667193
[TBL] [Abstract][Full Text] [Related]
14. Gastric Carcinomas With Lymphoid Stroma: An Evaluation of the Histopathologic and Molecular Features.
Hissong E; Ramrattan G; Zhang P; Zhou XK; Young G; Klimstra DS; Shia J; Fernandes H; Yantiss RK
Am J Surg Pathol; 2018 Apr; 42(4):453-462. PubMed ID: 29438172
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemistry in gynecologic carcinomas: Practical update with diagnostic and clinical considerations based on the 2020 WHO classification of tumors.
Buza N
Semin Diagn Pathol; 2022 Jan; 39(1):58-77. PubMed ID: 34750021
[TBL] [Abstract][Full Text] [Related]
16. PD-L1, RB1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type, of the uterine cervix.
Morgan S; Slodkowska E; Parra-Herran C; Mirkovic J
Histopathology; 2019 Jun; 74(7):997-1004. PubMed ID: 30667073
[TBL] [Abstract][Full Text] [Related]
17. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
Signorelli D; Giannatempo P; Grazia G; Aiello MM; Bertolini F; Mirabile A; Buti S; Vasile E; Scotti V; Pisapia P; Cona MS; Rolfo C; Malapelle U;
Biomed Res Int; 2019; 2019():9056417. PubMed ID: 31179334
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of mismatch repair deficiency screening in patients with mixed neuroendocrine non-neuroendocrine neoplasms (MiNEN).
Lou L; Lv F; Wu X; Li Y; Zhang X
Eur J Surg Oncol; 2021 Feb; 47(2):323-330. PubMed ID: 32907775
[TBL] [Abstract][Full Text] [Related]
19. Application of immunohistochemistry in gastrointestinal and liver neoplasms: new markers and evolving practice.
Chen ZE; Lin F
Arch Pathol Lab Med; 2015 Jan; 139(1):14-23. PubMed ID: 25549141
[TBL] [Abstract][Full Text] [Related]
20. Enrichment of
Mitra D; Clark JW; Shih HA; Oh KS; Brastianos PK; Wo JY; Strickland MR; Curry WT; Parikh AR; Corcoran RB; Ryan DP; Iafrate AJ; Borger DR; Lennerz JK; Hong TS
Oncologist; 2019 Feb; 24(2):193-201. PubMed ID: 30373904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
